96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,400 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 168 - 標的パスウェイ数 : 214

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05284136
(ClinicalTrials.gov)
April 1, 202228/2/2022Exclusion Diet vs corticosteroIds in patientS With activE Crohn's DiseaseProspective rAndomized Controlled tRial of Crohn's diseAse Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease - PARADISECrohn DiseaseDietary Supplement: Crohn's disease exclusion diet (CDED);Drug: Oral prednisoloneAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting16 Years70 YearsAll80Phase 2/Phase 3France;Netherlands
2NCT02517684
(ClinicalTrials.gov)
April 20151/7/2015Top-down Infliximab Study in Kids With Crohn's DiseaseTop-down Infliximab Study in Kids With Crohn's DiseaseCrohn's DiseaseDrug: Infliximab;Drug: Prednisolone;Other: Exclusive enteral nutrition;Drug: AzathioprineErasmus Medical CenterZonMw: The Netherlands Organisation for Health Research and Development;Hospira, now a wholly owned subsidiary of PfizerActive, not recruiting3 Years17 YearsAll100Phase 4Belgium;Finland;Netherlands;Denmark;Italy;Poland
3EUCTR2010-022017-26-GB
(EUCTR)
07/01/201108/12/2010A pilot study on the effects of an alternate-day corticosteroid regimen in children with active crohn’s disease - Alternate-day corticosteroid regimen in children with Crohn’s diseaseA pilot study on the effects of an alternate-day corticosteroid regimen in children with active crohn’s disease - Alternate-day corticosteroid regimen in children with Crohn’s disease Crohn's disease
MedDRA version: 12.;Level: LLT;Classification code 10013099;Term: Disease Crohns
Product Name: Prednisolone
INN or Proposed INN: Prednisolone
Central Manchester University Hospitals Foundation TrustNULLNot Recruiting Female: yes
Male: yes
27 Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4):United Kingdom
4NCT00609752
(ClinicalTrials.gov)
February 200824/1/2008Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's DiseaseAdverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's DiseaseCrohn DiseaseDrug: prednisolone;Dietary Supplement: Alicalm (polymeric liquid formula)University Hospital BirminghamSHS International;Children's Memorial Research Foundation;St George's University Hospital Research FoundationRecruiting7 Years17 YearsBoth80Phase 4United Kingdom
5EUCTR2006-003870-88-DE
(EUCTR)
27/11/200629/09/2006A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (COSPAR I). - COSPAR IA Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (COSPAR I). - COSPAR I In the present study, the corticosteroid-sparing effect of certolizumab pegol will be assessed in patients with moderate to severe Crohn’s disease who have received initial acute corticosteroid therapy (prednisone or prednisolone) for induction of remission.
MedDRA version: 8.1;Level: LLT;Classification code 10011401;Term: Crohn's disease
Product Name: certolizumab pegol
Product Code: CDP870
INN or Proposed INN: certolizumab pegol
UCB Pharma S.A.NULLNot RecruitingFemale: yes
Male: yes
352Phase 3Germany
6EUCTR2005-003337-40-GB
(EUCTR)
13/02/200613/01/2006Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTICAutologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTIC Patients with Crohn's disease who have not responded to immunosupressant medicationProduct Name: Cyclophosphamide
Product Code: N/A
INN or Proposed INN: cyclophosphamide
Other descriptive name: N/A
INN or Proposed INN: cyclophosphamide
Other descriptive name: N/A
Product Name: Filgrastim
Product Code: N/A
INN or Proposed INN: Filgrastim
Other descriptive name: N/A
Product Name: rabbit antithymocyte globulin
Product Code: rbATG
INN or Proposed INN: rabbit antithymocyte globulin
Other descriptive name: N/A
Product Name: Mesna
Product Code: N/A
INN or Proposed INN: mensa
Other descriptive name: N/A
Product Name: methyl prednisolone
Product Code: N/A
INN or Proposed INN: methyl prednisolone
Other descriptive name: N/A
Product Name: ciprofloxacin
Product Code: N/A
INN or Proposed INN: ciprofloxacin
Other descriptive name: N/A
European Group for Blood and Marrow Transplantation (EMBT)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48United Kingdom
7NCT00796250
(ClinicalTrials.gov)
November 1, 200321/11/2008Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)Efficacy of Infliximab as Bridging Therapy in the Treatment of Patients Affected by Corticodependent Crohn's Disease Under Standard Treatment With AzathioprineCrohn's DiseaseBiological: Infliximab;Drug: AZA;Drug: Placebo Prednisolone;Drug: Prednisolone;Biological: Placebo InfliximabMerck Sharp & Dohme Corp.NULLTerminated18 Years65 YearsAll9Phase 3NULL